Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what ...

Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Research analysts at William Blair cut their Q4 2025 earnings estimates for Fortrea in a research report issued to clients ...

A Durham company with a slumping stock is implementing changes to its board after reaching a deal with an activist investor.

BofA lowered the firm’s price target on Fortrea (FTRE) to $10 from $17 and keeps an Underperform rating on the shares after a Q4 miss and FY25 ...

Barclays lowered the firm’s price target on Fortrea (FTRE) to $12 from $25 and keeps an Equal Weight rating on the shares.Discover the Best ...

In a recent interview with Fierce Biotech's Chris Hayden, Fortrea's Chief Technology and Data Officer Alaric Jackson ...

Fortrea is a global, late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.

The contract-research organization expects $2.45 billion to $2.55 billion in revenue for 2025, down from $2.7 billion last year. Analysts polled by FactSet had been forecasting a small gain to $2.73 ...